Sallergen is an early-stage biotechnology company based in Sydney, Australia, focused on developing an intracutaneous allergen-specific immunotherapy to combat the rising prevalence of food allergies. Its proprietary technology enables direct delivery of allergens to immune cells in the skin's epidermis, aiming to modulate immune responses. By targeting these cells, Sallergen seeks to provide a more efficient and precise immunotherapy option, potentially offering long-term relief.